The current patent covers the test developed by us in cooperation with the Charité Berlin, AG Scheibenbogen, for the quantitative determination of antibodies directed against the ß-adrenergic receptor. A high antibody titer is an indication of the presence of chronic fatigue syndrome (CFS) and thus plays a decisive role in its diagnosis.